NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential
Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch.
The company has received constructive FDA feedback at its end of Phase 2 meeting for oral candidate bivamelagon, supporting plans to progress into Phase 3.
Rhythm is also working on broader commercial access, reimbursement, and geographic expansion in Europe and Japan for its rare neuroendocrine disease...